Sirnaomics Management Scientific Advisors

Prof. Jim Mixson
University of Maryland
Inventor of HKP
Dr. Mixson is a Scientific Founder of Sirnaomics and Professor at the University of Maryland. He is an expert in cancer, polymer design, and drug delivery. He spearheaded the HK (histidine-lysine) polymer nanoparticle technology for siRNA delivery in vitro and in vivo which is now demonstrating tremendous potential in delivery of RNAi therapeutics. Dr. Mixson’s laboratory is developing novel gene targeting approaches for treating cancer. He received his B.A. from Vanderbilt University and his M.D. degree from Emory University.
Prof. Daniel Von Hoff
Ex. AACR Pres. TD2
Oncology KOL
Dr. Von Hoff is a Physician in Chief and a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He also holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at Mayo Clinic Scottsdale, AZ. Dr. Von Hoff’s major interest is in the development of new anticancer agents. He is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.
Prof. P J Chen
U. Taiwan, Acad. Sinica
Liver Cancer KOL
Professor Chen holds several faculty positions at the National Taiwan University, including Professor of Medicine and Director of the Medical College. His areas of expertise and research interests include molecular biology of hepatic viruses, treatment of liver cancers and prevention and treatment of other hepatic diseases. Dr. Chen received his M.D, from National Taiwan University and Ph.D. from University of Pennsylvania Medical School. He is a Member of National Academia of Taiwan (Academia Sinica).
Prof. Bernard Lebleu
Universite Montpellier
Polypeptide KOL
Bernard Lebleu received his Ph.D in Biochemistry from University Brussel, Belgium (1973), and was EMBO fellow, Weizmann Institute (1970–72); INSERM fellow, Curie Institute, Paris (1973–74); Research associate, Yale University (1975–76); Professor of Molecular Biology, University Montpellier 2, France (since 1978). Prof. Lebleu was Group leader at Molecular Genetics Institute (until 1993) and at the CNRS Laboratory of Dynamique des interactions membranaires normales et pathologiques. Research on post-transcriptional regulation in eucaryotes focusing on interferon mechanism of action (1973–2004) and nucleic acids delivery (since 1989) with over 200-peer reviewed publications.
Prof. John Harmon
Johns Hopkins
Tumor Surgery KOL
John W. Harmon, M.D., FACS, professor of surgery at The Johns Hopkins University School of Medicine and director of surgical research at the Johns Hopkins Bayview Medical Center, earned a medical degree at the Columbia University College of Physicians and Surgeons in New York and received surgical training at the Harvard University Medical School. Dr. John Harmon is a senior surgeon with extensive experience dealing with a wide variety of surgical problems. Prior to being appointed Professor of Surgery at Johns Hopkins, he was an Army surgeon stationed at Walter Reed, and then Chief of Surgery at the Washington VA Medical Center. His current practice is focused on complex hernia, breast cancer, and surgical conditions of the thyroid and parathyroid.
Dr. Brian Harvey, MD/PhD
Ex. FDA CDER GI Director
Liver Fibrosis KOL
Dr. Brian Harvey is a former Vice President of U.S. Regulatory Strategy at Pfizer. He also worked at the USFDA as Director of the Division of Gastroenterology Products. Dr. Harvey led the regulatory review for NDA and BLA submissions of major breakthrough drugs, including Humira, Remicade and Lialda. Throughout his FDA career, Dr. Harvey remained a practicing clinician at the Anne Arundel Medical Center in Maryland. He graduated with honors from Middlebury College in Vermont and earned his Ph.D. and M.D. at the University of Connecticut.
Prof. Brian Berman
University of Miami
Skin Cancer KOL
Dr. Brian Berman is Professor of Dermatology at The University of Miami Miller School of Medicine and has the honor of serving as a member of the Board of Directors of the American Academy of Dermatology. He has served as Professor of Dermatology and Internal Medicine at the University of Miami, Medical Director for Dermatology for inpatient and outpatients at Dade County’s Jackson Memorial Hospital, Professor of Dermatology and Vice-Chairman of the Department of Dermatology at The University of California, Davis, Chief of the Dermatology Service at the VA Medical Center, Martinez, CA, and Chairman of the Department of Dermatology at The Mount Sinai Medical Center in Miami Beach, Florida. He is past President and Founder of The National Association of Veterans Affairs Dermatologists.
Prof. Al Benson, III
Northwest University
Liver Cancer KOL
Al B. Benson, III, MD, has served on a number of American Society of Clinical Oncology (ASCO) committees and is currently a member of the Task Force on Quality of Cancer Care, the co-chair of ASCO’s Colorectal Cancer Guidelines Subcommittee, the Stage II Colon Cancer Guidelines Panel and the Guidelines Panel for use of Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. He is also chair of the Eastern Cooperative Oncology Group Gastrointestinal and Data Monitoring Committees. Benson’s research is primarily in the areas of gastrointestinal cancer clinical trials, cancer clinical trials, biologic therapies, phase I cancer clinical trials and cancer guideline development. He has authored or coauthored numerous reports, reviews and book chapters that focus on these topics. His research in biologic agents, cancer therapy and cancer prevention has been awarded funding from a variety of sources, including the NIH.